Anti-BLyS antibody
US9828423B2 · kind B2 · utility
2Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 22, 2013 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Dec 24, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P21/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and/or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.